7Baggers
 biomea fusion explores breakthrough in menin inhibition for diabetes  Traders Union Tue, 11 Nov 2025 07:03:14 GMT
 BMEA: Citigroup Lowers Price Target but Maintains 'Buy' Rating |  GuruFocus Tue, 11 Nov 2025 04:34:34 GMT
 bmea: citigroup lowers price target but maintains 'buy' rating |  GuruFocus Mon, 10 Nov 2025 22:33:16 GMT
 Biomea Fusion price target lowered to $6 from $7 at Citi  TipRanks Mon, 10 Nov 2025 12:44:02 GMT
 Biomea Fusion to Participate at Jefferies London Healthcare Conference  Yahoo Finance Mon, 10 Nov 2025 12:00:00 GMT
 biomea fusion stock price target lowered to $12 at d. boral capital  Investing.com Australia Thu, 06 Nov 2025 08:01:11 GMT
 biomea fusion (nasdaq:bmea) announces earnings results  MarketBeat Wed, 05 Nov 2025 23:06:20 GMT
 biomea fusion : 2025 kirschberg obesityweek poster bmf 650  MarketScreener Wed, 05 Nov 2025 18:48:09 GMT
 biomea fusion stock price target lowered to $12 at d. boral capital  Investing.com Wed, 05 Nov 2025 13:22:27 GMT
 biomea fusion inc. reports q3 2025 financial results  TipRanks Wed, 05 Nov 2025 05:20:09 GMT
 biomea fusion reports q3 eps (27c), consensus (29c)  TipRanks Wed, 05 Nov 2025 01:44:04 GMT
 Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights  Investing News Network Tue, 04 Nov 2025 08:00:00 GMT
 Biomea Fusion Inc. Reports Q3 2025 Financial Results  TipRanks Tue, 04 Nov 2025 08:00:00 GMT
 biomea fusion (nasdaq:bmea) shares down 2.9% - here's why  MarketBeat Tue, 04 Nov 2025 07:34:44 GMT
 biomea fusion shares continue steep descent amid technical weakness  AD HOC NEWS Fri, 31 Oct 2025 07:34:04 GMT
 Biomea Fusion’s BMF-650: A New Hope in Obesity Treatment?  TipRanks Fri, 31 Oct 2025 07:00:00 GMT
 Biomea Fusion to Present Poster Presentations at ObesityWeek®2025  Yahoo Finance Thu, 30 Oct 2025 07:00:00 GMT
 First patient dosed in Biomea Fusion’s Phase I trial of BMF-650 for obesity  Clinical Trials Arena Tue, 28 Oct 2025 07:00:00 GMT

Biomea Fusion, Inc.
(NASDAQ:BMEA) 

BMEA stock logo

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibit...

Founded: 2017
CEO: Thomas Butler  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends